"HIV-1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.
| Descriptor ID |
D015497
|
| MeSH Number(s) |
B04.820.650.589.650.350.400
|
| Concept/Terms |
HIV-1- HIV-1
- Human immunodeficiency virus 1
- HIV-I
- Immunodeficiency Virus Type 1, Human
- Human Immunodeficiency Virus Type 1
|
Below are MeSH descriptors whose meaning is more general than "HIV-1".
Below are MeSH descriptors whose meaning is more specific than "HIV-1".
This graph shows the total number of publications written about "HIV-1" by people in this website by year, and whether "HIV-1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 4 | 0 | 4 |
| 1998 | 4 | 1 | 5 |
| 1999 | 3 | 0 | 3 |
| 2000 | 11 | 0 | 11 |
| 2001 | 9 | 1 | 10 |
| 2002 | 12 | 2 | 14 |
| 2003 | 10 | 3 | 13 |
| 2004 | 12 | 4 | 16 |
| 2005 | 18 | 3 | 21 |
| 2006 | 24 | 1 | 25 |
| 2007 | 25 | 0 | 25 |
| 2008 | 24 | 3 | 27 |
| 2009 | 31 | 10 | 41 |
| 2010 | 35 | 11 | 46 |
| 2011 | 33 | 7 | 40 |
| 2012 | 29 | 8 | 37 |
| 2013 | 22 | 5 | 27 |
| 2014 | 23 | 14 | 37 |
| 2015 | 39 | 5 | 44 |
| 2016 | 22 | 13 | 35 |
| 2017 | 28 | 11 | 39 |
| 2018 | 30 | 9 | 39 |
| 2019 | 27 | 20 | 47 |
| 2020 | 30 | 11 | 41 |
| 2021 | 33 | 6 | 39 |
| 2022 | 25 | 2 | 27 |
| 2023 | 15 | 0 | 15 |
| 2024 | 7 | 5 | 12 |
To return to the timeline,
click here.
Below are the most recent publications written about "HIV-1" by people in Profiles.
-
Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120. J Infect Dis. 2024 Aug 16; 230(2):e405-e415.
-
Characterizing HIV drug resistance in cases of vertical transmission in the VESTED randomized antiretroviral treatment trial. J Acquir Immune Defic Syndr. 2024 Aug; 96(4):385-392.
-
SARS-CoV-2 humoral immunity in people living with HIV-1. Trends Immunol. 2024 Jul; 45(7):511-522.
-
Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir- and Tenofovir Alafenamide Fumarate-Containing Antiretroviral Treatment Regimens During Pregnancy and Postpartum. Clin Infect Dis. 2024 Jun 14; 78(6):1617-1628.
-
Evaluating the antibody response elicited by diverse HIV envelope immunogens in the African green monkey (Vervet) model. Sci Rep. 2024 06 10; 14(1):13311.
-
D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15?years. Contemp Clin Trials. 2024 Jul; 142:107540.
-
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial. PLoS Med. 2024 Mar; 21(3):e1004360.
-
Assessment of the performance of the plasma separation card for HIV-1 viral load monitoring in South Africa. J Clin Microbiol. 2024 Apr 10; 62(4):e0164923.
-
Higher CCR5 density on CD4 + T-cells in mothers and infants is associated with increased risk of in-utero HIV-1 transmission. AIDS. 2024 06 01; 38(7):945-954.
-
Determinants of early change in serum creatinine after initiation of dolutegravir-based antiretroviral therapy in South Africa. Br J Clin Pharmacol. 2024 May; 90(5):1247-1257.